With deramiocel's BLA submission and solid data, CAPR presents a compelling investment opportunity, trading below projected sales estimates despite recent price increases. …deramiocel was ...

Capricor Therapeutics (NASDAQ:CAPR) just reported results for the first quarter of 2024. Capricor Therapeutics reported earnings per share of -31 cents. This was below the analyst estimate for EPS ...

CAPR has been the subject of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $77.00 price target on shares of Capricor Therapeutics in a report on Thursday ...

In this article, we are going to take a look at where Capricor Therapeutics, Inc. (NASDAQ:CAPR) stands against other best small-cap growth stocks to buy now. On November 4, 2024, Nick Sheridan ...